AUS
NZ
UK
CA
USA
IND
Highlights
- Sigma earnings up 36% in nine months
- $42.4 million merger transaction costs recorded
- New $36 billion group now includes nearly 1,000 stores
Sigma Healthcare (ASX:SIG) has reported a robust 36% surge in pre-tax earnings for the nine months ending March, underscoring the momentum gained from its recent merger with Chemist Warehouse. The strategic tie-up, finalized in February, positions the group as a formidable $36 billion pharmacy powerhouse with close to 1,000 outlets and $1 billion in annual earnings.
While Sigma didn’t disclose consolidated earnings for the merged entity, it confirmed that growth in earnings before interest and tax (EBIT), excluding merger-related expenses, closely mirrored Chemist Warehouse’s performance for the first half of the fiscal year. Chemist Warehouse had earlier posted a 36% rise in EBIT to $446.1 million during that period.
A key financial note from the announcement was the $42.4 million transaction cost incurred during the merger. This figure reflects the scale and complexity of the reverse takeover structure, which saw Chemist Warehouse merge into Sigma, approved by shareholders back in January.
The integration of Sigma and Chemist Warehouse creates a vertically integrated retail and wholesale pharmacy network, significantly reshaping the competitive landscape in Australia’s healthcare retail space. With almost 1,000 locations now under one umbrella, the consolidated group is expected to benefit from enhanced distribution capabilities and streamlined operations.
The development is of particular interest to those tracking ASX200 companies, as Sigma’s strategic merger adds substantial weight to the retail pharmacy segment within the broader index. The scale of this merger and the solid performance metrics reinforce confidence in sectors with essential services and recurring demand.
Additionally, Sigma's profile fits within the interest area of investors exploring ASX dividend stocks. With its expanded market presence and operational efficiencies post-merger, the newly formed group may present stable dividend opportunities moving forward, a point of consideration for income-focused portfolios.
As the company continues to integrate and streamline its operations, all eyes will be on how the synergy benefits translate into long-term earnings and shareholder value across Australia's competitive pharmacy sector.
